Stocktoria
STRATA Skin Sciences, Inc. SSKN
STRATA Skin Sciences, Inc. (SSKN) earns a Piotroski F-score of 4/9 (mixed financial health). It does not currently pay a dividend. FY2025 revenue was $30.7M at a -20.4% net margin.
Price from month-end closes (Yahoo) — for reference, not real-time.
Beneish M-score: -3.31 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
How it ranks in Manufacturing · percentile among 1906 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SSKN | STRATA Skin Sciences, Inc. | 4/9 | — | — | -8.5% |
| OBIO | Orchestra BioMed Holdings, Inc. | 5/9 | -7.02 | — | — |
| SRTS | Sensus Healthcare, Inc. | 4/9 | 14.36 | — | -34.3% |
| CTSO | Cytosorbents Corp | 3/9 | — | — | +4.1% |
| UTMD | UTAH MEDICAL PRODUCTS INC | 3/9 | — | — | -5.8% |
| IDXG | INTERPACE BIOSCIENCES, INC. | 4/9 | -16.52 | 1.9 | -17.5% |
| BDMD | Baird Medical Investment Holdings Ltd | 1/9 | 0.49 | — | -39.2% |
FAQ
Is SSKN financially healthy?
STRATA Skin Sciences, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak).
Does SSKN pay a dividend?
No, STRATA Skin Sciences, Inc. does not currently pay a dividend.
How profitable is SSKN?
In FY2025, STRATA Skin Sciences, Inc. had a net margin of -20.4% and a return on equity of -215.3%.
Source: SEC EDGAR filings · CIK 0001051514 · US · as of 2025-12-31. facts plus Stocktoria's own computed scores — not investment advice.